Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia

    ... the humanized anti-CD52 monoclonal antibody , alemtuzumab , might be active in SAA due to its lymphocytotoxic properties. To test this hypothesis, we investigated alemtuzumab monotherapy from 2003-2010 in treatment-naïve, relapsed, and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

    ... This retrospective national study compared the use of alemtuzumab -based conditioning regimens for hematopoietic SCT (HSCT) in ... (ATG)-based regimens. One hundred patients received alemtuzumab and 55 ATG-based regimens. A matched sibling donor (MSD) was used ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

    ... We evaluated a novel alemtuzumab -based conditioning regimen in hematopoietic stem cell ... 4 days, cyclophosphamide 300mg/m(2) for 4 days and alemtuzumab median total dose of 60mg (range:40-100mg). Median age was 35 ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab

    Journal Title:  Semin Hematol Primary Author:  Parikh AR Author(s):  Parikh A...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

    Journal Title:  Leuk Res. Primary Author:  Cheng KL Author(s):  Cheng KL, Br...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.

    ... Alemtuzumab , a humanized anti-CD52, IgG1 monoclonal antibody , is ... severe aplastic anaemia (SAA). We have reviewed the use of alemtuzumab-based conditioning regimen for HSCT in SAA and show that it results ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Antibodies in the treatment of aplastic anemia.

    ... proposed and new antibodies have emerged: porcine ATG, alemtuzumab , daclizumab , and rituximab. Experience with these antibodies is limited to a few studies with alemtuzumab being the most promising, but the results are interesting and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Recent Developments in Drug Therapy for Aplastic Anemia

    ... for nonsevere AA (NAA); however, data is limited. Alemtuzumab or eltrombopag are options for relapsed AA in select ... are needed before this is adopted into clinical practice. Alemtuzumab and eltrombopag have been studied for treatment of AA; recruiting ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties

    ... other than h-ATG (rabbit-ATG, cyclophosphamide , alemtuzumab ) has not reproduced the positive outcome seen with standard ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Targeting immune dysregulation in myelodysplastic syndromes.

    ... After treatment with a clinical protocol using alemtuzumab , an anti-CD52 antibody, her blood cell counts returned to ...

    Research Article last updated 07/20/2018 - 5:14pm.